Mallinckrodt PLC
MNK.N- Latest Trade
- trading higher1.5USD
- 0.05
- 3.45%
- As of Jun 6 2023. Values delayed up to 15 minutes
- Today's Range
- 1.50 - 1.50
- 52 Week Range
- 1.16 - 18.00
- Previous Close
- 1.45
- Open
- 1.50
- Volume
- 300.00
- 3 Month Average Trading Volume
- 0.00
- Shares Out (Mil)
- 97.91
- Market Cap
- 149.49
- Forward P/E
- -99,999.99
- Dividend Yield
- 0.00
Key Statistics
- P/E Excl. Extra Items (TTM)
- 0.00
- Price To Sales (TTM)
- 0.07
- Price To Book (Quarterly)
- 4.93
- Price To Cash Flow (Per Share TTM)
- 0.00
- Total Debt/Total Equity (Quarterly)
- 712.56
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -9.97
- Return On Equity (TTM)
- -7.71
2021 (millions USD)
About Mallinckrodt PLC (MNK.N)
Company Information
Mallinckrodt plc develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredients (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its products include Acthar Gel, INOmax, Ofirmev, Therakos and Amitiza.
Address
College Business & Technology Park Cruiserath, BlanchardstownDUBLIN,
null
Ireland
Industry
Major Drugs
Executive Leadership
- Paul M. Bisaro
- Independent Chairman of the Board
- Sigurdur Olafsson
- President, Chief Executive Officer, Director
- Bryan M. Reasons
- Chief Financial Officer, Executive Vice President
- Kassie Harrold
- Executive Vice President, Chief Compliance Officer
- Mark Tyndall
- Executive Vice President, Chief Legal Officer, Corporate Secretary
- Lisa French
- Executive Vice President, Chief Commercial Officer
- Jason Goodson
- Executive Vice President, Head of Corporate Development
- Henriette Nielsen
- Executive Vice President, Chief Transformation Officer
- Peter C. Richardson
- Executive Vice President, Chief Scientific Officer
- Stephen G. Welch
- Executive Vice President, Head of Specialty Generics
- Daniel A. Celentano
- Independent Director
- Riad H. El- Dada
- Independent Director
- Neal P. Goldman
- Independent Director
- Karen L. Ling
- Independent Director
- Woodrow A. Myers
- Independent Director
- Susan A. Silbermann
- Independent Director
- James R. Sulat
- Independent Director
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,965.50 | -- |
| Copper | 722.45 | 0.18% |
| Brent Crude Oil | 76.35 | 0.08% |
| CBOT Soybeans | 1,357.75 | 0.33% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,283.85 | 0.24% |
| Euro STOXX 50 | 4,295.22 | 0.05% |
| FTSE 100 | 7,628.10 | 0.37% |
| Nikkei 225 | 32,658.11 | 0.47% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes